Theravance and Glaxo say asthma study succeeded

NEW YORK (AP) — Theravance and GlaxoSmithKline said Friday that their lung disease drug Breo Ellipta worked as a treatment for asthma in a clinical trial.

The companies said patients who took Breo Ellipta had a bigger improvement in lung function than patients who took the drug Flonase, which contains one of Breo Ellipta’s two main components. Breo Ellipta is approved as a treatment for chronic obstructive pulmonary disease.

The most common side effects of treatment included headache, upper respiratory tract infection, and flu.

The companies launched the drug in the U.S. on Oct. 30. The drug is also approved in Canada and Japan. It is sold in Japan as Relvar Ellipta.

Shares of California-based Theravance Inc. picked up 98 cents, or 2.8 percent, to $36.53 in late morning trading. GlaxoSmithKline PLC’s U.S. shares rose 30 cents to $52.52.

KSN.com provides commenting to allow for constructive discussion on the stories we cover. In order to comment here, you acknowledge you have read and agreed to our Terms of Service. Commenters who violate these terms, including use of vulgar language, racial slurs or consistent name calling will be banned. Please be respectful of the opinions of others. If you see an inappropriate comment, please flag it for our moderators to review.

blog comments powered by Disqus